2. Signaling Pathways
  3. GPCR/G Protein
  4. Oxytocin Receptor
  5. Oxytocin Receptor Antagonist

Oxytocin Receptor Antagonist

Oxytocin Receptor Antagonists (24):

Cat. No. Product Name Effect Purity
  • HY-108677
    L-368,899 hydrochloride
    		Antagonist 98.78%
    L-368,899 hydrochloride is a potent, selective, orally bioavailable, non-peptide oxytocin receptor antagonist, with IC50s of 8.9 nM and 26 nM for rat uterus and human uterus oxytocin receptor, respectively. L-368,899 hydrochloride used as a tocolytic agent.
  • HY-17572A
    Atosiban acetate
    		Antagonist 99.88%
    Atosiban acetate (RW22164 acetate;RWJ22164 acetate) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research.
  • HY-15007
    L 366509
    		Antagonist
    L 366509 is a spiroindenylpiperidine camphorsulfonamide oxytocin (OT) antagonist. Modifications led to a new series of o-tolylpiperazine (TP) camphorsulfonamides, exhibiting high affinity for OT receptors and selectivity over arginine vasopressin receptors. Notably, compound 7 (L-368,899) showed excellent OT receptor affinity, potency in inhibiting OT-stimulated uterine contractions, good aqueous solubility, and oral bioavailability in multiple species. Compound 7 has entered clinical testing as an oral and intravenous tocolytic agent. Molecular modeling suggests the TP camphorsulfonamide structure mimics the D-AA2-Ile3 dipeptide, crucial in potent OT antagonists.
  • HY-15018A
    SSR126768A free base
    		Antagonist
    SSR126768A free base is an orally active antagonist for oxytocin receptor, with Ki of 0.44 nM. SSR126768A free base is a tocolytic agent, that antagonizes the Oxytocin (HY-17571)-induced intracellular Ca2+ increase and prostaglandin release in human uterine smooth muscle cells, inhibits thus the Oxytocin (HY-17571)-induced uterine contraction and delays parturition in pregnant rats in labor.
  • HY-129333
    L-364918
    		Antagonist
    L-364918 is a potent and selective oxytocin and arginine vasopressin antagonist with Ki values of 30, 1300, 2400 nM for OT, AVP-V1, AVP-V2, respectively. L-364918 has the potential for the research of preterm labor and disturbances in water balance.
  • HY-17572
    Atosiban
    		Antagonist 99.55%
    Atosiban (RW22164; RWJ22164) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research.
  • HY-15010
    L-371,257
    		Antagonist 99.90%
    L-371,257 is an orally bioavailable, non-blood-brain barrier penetrant, selective and competitive antagonist of oxytocin receptor (pA2=8.4) with high affinity at both the oxytocin receptor (Ki=19 nM) and vasopressin V1a receptor (Ki=3.7 nM).
  • HY-15023
    Cligosiban
    		Antagonist 99.88%
    Cligosiban (PF-3274167) is an orally active, highly selective, and centrally permeable oxytocin receptor antagonist with good pharmacokinetics in rats and can inhibit physiological ejaculation in rodents[1][2].
  • HY-14778
    Retosiban
    		Antagonist 98.97%
    Retosiban (GSK221149A) is a potent and selective oxytocin antagonist with a Ki of 0.65 nM.
  • HY-128351
    SHR1653
    		Antagonist 99.69%
    SHR1653 is a highly potent, selective and brain penetrated oxytocin receptor (OTR) antagonist, with an IC50 of 15 nM for hOTR.
  • HY-15015A
    OT-R antagonist 2
    		Antagonist 99.86%
    OT-R antagonist 2 is a nonpeptide low molecular weight OT-R antagonist.
  • HY-15015
    OT-R antagonist 1
    		Antagonist ≥98.0%
    OT-R antagonist 1 is a new potent and selective nonpeptide low molecular weight OT-R antagonist.
  • HY-105018
    Epelsiban
    		Antagonist
    Epelsiban (GSK 557296) is a potent, selective and orally bioavailable oxytocin receptor antagonist, with a pKi of 9.9 for human oxytocin receptor.
  • HY-103649
    OT antagonist 3
    		Antagonist
    OT antagonist 3 is an oxytocin (OT) antagonist extracted from patent WO2007017752A1.
  • HY-P3516
    Barusiban
    		Antagonist
    Barusiban (FE-200440) is an oxytocin receptor (OT-R) antagonist (Ki=0.8 nM), inhibits OT-induced contraction. Barusiban can be used in preterm labor (PTL), in vitro fertilisation (IVF) and infertility research.
  • HY-15008
    L-368,899
    		Antagonist
    L-368,899 is an orally active and selective OT (oxytocin ) receptor antagonist, with IC50s of 8.9 and 26 nM for uterus of rat and human, respectively. L-368,899 can cross the blood-brain barrier (BBB). L-368,899 inhibits oxytocin-stimulated uterine contractions in rats and can be used in study of preterm labor.
  • HY-P4895
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin
    		Antagonist
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease.
  • HY-103650
    OT antagonist 1
    		Antagonist
    OT antagonist 1 (Compound 4) is a potent, selective Oxytocin antagonist with a Ki of 50 nM.
  • HY-P2014
    (d(CH2)51,Tyr(Me)2,Thr4,Orn8,Tyr-NH29)-Vasotocin
    		Antagonist
    (d(CH2)51,Tyr(Me)2,Thr4,Orn8,Tyr-NH29)-Vasotocin is an oxytocin antagonist and can be used for the research of sexual behavior.
  • HY-15011
    L-372662
    		Antagonist 98.70%
    L-372662 is a potent and orally active non-peptide oxytocin antagonist with a Ki value of 4.8. The Kd value of L-372662 for wild-type hOTR and [A318G]OTR is 5.8 nM and 73 nM. L-372662 shows selectivity to OTR:V1aR.